Oxford StemTech produces human stem cells for research and drug discovery. The full potential of induced pluripotent stem cells (iPSC) is not being realised because current reprogramming methods are labour-intensive, low-throughput and costly. StemTech has developed a novel method that drastically reduces the cost and hugely increases the scale of reprogramming to produce the highest quality stem cell lines. Our ability to rapidly produce iPSCs at scale allows precision medicine research and drug discovery on large cohorts of patients. At StemTech, we would like to support your goals to better understand disease, discover novel drug targets and get medicines that work into clinic.
| Website | https://www.oxfordstemtech.com |
| Employees | 10 (5 on RocketReach) |
| Founded | 2020 |
| Phone | +44 1869 238035 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+8 more
(view full list)
|
| Industry | Biotechnology |
| Keywords | Stem Cell Research, Drug Discovery, Pharmaceutical Research, Pluripotent Stem Cells, Preclinical Research, Regenerative Medicine, Cell Culture, Cellular Reprogramming, Disease Modeling, Cell Therapy, Therapeutic Applications, Biomanufacturing, Biotechnology, Clinical Trials, Life Sciences, Research Tools, Scientific Research |
| Competitors | GE HealthCare, Thermo Fisher Scientific, Merck Group, Agilent Technologies, Illumina, PerkinElmer, Inc., Bio-Rad Laboratories, QIAGEN, Miltenyi Biotec, Fisher Scientific +36 more (view full list) |
Looking for a particular Oxford StemTech employee's phone or email?
Galbha Duggal is the Chief Scientific Officer, Co-Founder of Oxford StemTech.
5 people are employed at Oxford StemTech.